3 state legislative battles to watch in 2019

(By Lev Facher for STAT)

WASHINGTON — Drug pricing is on the agenda here in 2019. But with Republicans controlling the Senate and Democrats controlling the House — and neither party fully on board with the White House’s work on drug pricing — the next two years are unlikely to be an era of wholesale change for the country’s health care system or how prescription medicines are priced.  Continue reading article here…

Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.


Leave a Reply